Mayne Pharma Group (ASX:MYX) - Aandelenkoers, Nieuws & Analyse

MYX Overzicht aandelen

MYX fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 110.04% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Mayne Pharma Group Limited Concurrenten

Vita Life Sciences

ASX:VLS

AU$118.4m

Incannex Healthcare

ASX:IHL

AU$65.1m

Medical Developments International

ASX:MVP

AU$50.7m

Syntara

ASX:SNT

AU$59.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Mayne Pharma Group
Historische aandelenkoersen
Huidige aandelenkoers	AU$4.43
52 Week Hoogtepunt	AU$7.46
52 Week Laag	AU$3.74
Bèta	1.24
11 maand verandering	-1.56%
3 maanden verandering	14.18%
1 Jaar Verandering	10.75%
33 jaar verandering	-27.38%
5 jaar verandering	-61.14%
Verandering sinds IPO	-63.08%

Recent nieuws en updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Rendement voor aandeelhouders

	MYX	AU Pharmaceuticals	AU Markt
7D	3.0%	3.4%	0.2%
1Y	10.8%	64.3%	16.6%

Rendement versus industrie: MYX presteerde slechter dan de Australian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 64.3 % opleverde.

Rendement versus markt: MYX presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 16.6 % opleverde.

Prijsvolatiliteit

Is MYX's price volatile compared to industry and market?
MYX volatility
MYX Average Weekly Movement	7.0%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.5%

Stabiele aandelenkoers: MYX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van MYX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2005	n/a	Shawn O’Brien	www.maynepharma.com

Mayne Pharma Group Limited, een gespecialiseerd farmaceutisch bedrijf, produceert en verkoopt merk- en generieke farmaceutische producten in Australië, Nieuw-Zeeland, de Verenigde Staten, Canada, Europa en Azië. Het bedrijf is actief in drie segmenten: Vrouwengeneeskunde, Dermatologie en Internationaal. Het bedrijf levert systemen voor orale toediening van geneesmiddelen en contractontwikkelings- en productiediensten aan derden en distribueert farmaceutische specialiteiten in de therapeutische gebieden dermatologie, vrouwengeneeskunde en infectieziekten.

Mayne Pharma Group Limited Samenvatting

Hoe verhouden de winst en inkomsten van Mayne Pharma Group zich tot de beurswaarde?
MYX fundamentele statistieken
Marktkapitalisatie	AU$359.49m
Inkomsten(TTM)	-AU$168.62m
Inkomsten(TTM)	AU$388.40m

0.9x

P/S-verhouding

-2.1x

Koers/Winstverhouding

Is MYX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MYX resultatenrekening (TTM)
Inkomsten	AU$388.40m
Kosten van inkomsten	AU$169.62m
Brutowinst	AU$218.78m
Overige uitgaven	AU$387.39m
Inkomsten	-AU$168.62m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.08
Brutomarge	56.33%
Nettowinstmarge	-43.41%
Schuld/Eigen Vermogen Verhouding	7.0%

Hoe presteerde MYX op de lange termijn?

Bekijk historische prestaties en vergelijking

MYX Overzicht aandelen

Beloningen

Risicoanalyse

Mayne Pharma Group Limited Concurrenten

ASX:VLS

AU$118.4m

ASX:IHL

AU$65.1m

ASX:MVP

AU$50.7m

ASX:SNT

AU$59.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope